Arseneault, L, Cannon, M, Witton, J, Murray, RM (2004). Causal association between cannabis and psychosis: examination of the evidence. British Journal of Psychiatry 184, 110–117.
Bangalore, SS, Prasad, KMR, Montrose, DM, Goradia, DD, Diwadkar, VA, Keshavan, MS (2008). Cannabis use and brain structural alterations in first episode schizophrenia – a region of interest, voxel based morphometric study. Schizophrenia Research 99, 1–6.
Bebbington, P, Wilkins, S, Jones, P, Foerster, A, Murray, R, Toone, B, Lewis, S (1993). Life events and psychosis. Initial results from the Camberwell Collaborative Psychosis Study. British Journal of Psychiatry 162, 72–79.
Boos, H, Aleman, A, Cahn, W, Hulshoff Pol, H, Kahn, RS (2007). Brain volumes in relatives of patients with schizophrenia: a meta-analysis. Archives of General Psychiatry 64, 297–304.
Borgwardt, SJ, McGuire, PK, Aston, J, Gschwandtner, U, Pflüger, MO, Stieglitz, RD, Radue, EW, Riecher-Rössler, A (2008). Reductions in frontal, temporal and parietal volume associated with the onset of psychosis. Schizophrenia Research 106, 108–114.
Chan, RCK, Di, X, McAlonan, GM, Gong, Q (2011). Brain anatomical abnormalities in high-risk individuals, first-episode, and chronic schizophrenia: an activation likelihood estimation meta-analysis of illness progression. Schizophrenia Bulletin 37, 177–188.
Demirakca, T, Sartorius, A, Ende, G, Meyer, N, Welzel, H, Skopp, G, Mann, K, Hermann, D (2011). Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabidiol. Drug and Alcohol Dependence 114, 242–245.
Diwadkar, VA, Montrose, DM, Dworakowski, D, Sweeney, JA, Keshavan, MS (2006). Genetically predisposed offspring with schizotypal features: an ultra high-risk group for schizophrenia? Progress in Neuro-Psychopharmacology and Biological Psychiatry 30, 230–238.
Ellison-Wright, I, Glahn, DC, Laird, AR, Thelen, SM, Bullmore, E (2008). The anatomy of first-episode and chronic schizophrenia: an anatomical likelihood estimation meta-analysis. American Journal of Psychiatry 165, 1015–1023.
El Khoury, MA, Gorgievski, V, Moutsimilli, L, Giros, B, Tzavara, ET (2012). Interactions between the cannabinoid and dopaminergic systems: evidence from animal studies. Progress in Neuro-Psychopharmacology and Biological Psychiatry 38, 36–50.
Emerton, BC, Jerram, M, Deckersbach, T, Dougherty, DD, Fulwiler, C, Gansler, DA (2009). A comparison of voxel-based morphometry and volumetry methods in the context of the neural basis of aggression. Brain Imaging and Behavior 3, 332–341.
Fusar-Poli, P, Borgwardt, S, Crescini, A, D'Este, G, Kempton, M, Lawrie, S, Guire, PM, Sacchetti, E (2011). Neuroanatomy of vulnerability to psychosis: a voxel-based meta-analysis. Neuroscience and Biobehavioral Reviews 35, 1175–1185.
Giuliani, NR, Calhoun, VD, Pearlson, GD, Francis, A, Buchanan, RW (2005). Voxel-based morphometry versus region of interest: a comparison of two methods for analyzing gray matter differences in schizophrenia. Schizophrenia Research 74, 135–147.
Habets, P, Marcelis, M, Gronenschild, E, Drukker, M, van Os, J; Genetic Risk and Outcome of Psychosis (G. R. O. U.P.) (2011). Reduced cortical thickness as an outcome of differential sensitivity to environmental risks in schizophrenia. Biological Psychiatry 69, 487–494.
Hall, W, Degenhardt, L (2006). What are the policy implications of the evidence on cannabis and psychosis? Canadian Journal of Psychiatry 51, 566–574.
Hodges, A, Byrne, M, Grant, E, Johnstone, E (1999). People at risk of schizophrenia. Sample characteristics of the first 100 cases in the Edinburgh High-Risk Study. British Journal of Psychiatry 174, 547–553.
Honea, R, Crow, TJ, Passingham, D, Mackay, CE (2005). Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. American Journal of Psychiatry 162, 2233–2245.
Job, DE, Whalley, HC, Johnstone, EC, Lawrie, SM (2005). Grey matter changes over time in high risk subjects developing schizophrenia. NeuroImage 25, 1023–1030.
Job, DE, Whalley, HC, McConnell, S, Glabus, M, Johnstone, EC, Lawrie, SM (2003). Voxel-based morphometry of grey matter densities in subjects at high risk of schizophrenia. Schizophrenia Research 64, 1–13.
Kahn, RS, Linszen, H, van Os, J, Wiersma, D, Bruggeman, R, Cahn, W, de Haan, L, Krabbendam, L, Myin-Germeys, I (2011). Evidence that familial liability for psychosis is expressed as differential sensitivity to cannabis: an analysis of patient-sibling and sibling-control pairs. Archives of General Psychiatry 68, 138–147.
Kipps, CM, Duggins, AJ, Mahant, N, Gomes, L, Ashburner, J, McCusker, EA (2005). Progression of structural neuropathology in preclinical Huntington's disease: a tensor based morphometry study. Journal of Neurology, Neurosurgery and Psychiatry 76, 650–655.
Konick, LC, Friedman, L (2001). Meta-analysis of thalamic size in schizophrenia. Biological Psychiatry 49, 28–38.
Lawrie, SM, Abukmeil, SS (1998). Brain abnormality in schizophrenia. A systematic and quantitative review of volumetric magnetic resonance imaging studies. British Journal of Psychiatry 172, 110–120.
Lawrie, SM, McIntosh, AM, Hall, J, Owens, DGC, Johnstone, EC (2008). Brain structure and function changes during the development of schizophrenia: the evidence from studies of subjects at increased genetic risk. Schizophrenia Bulletin 34, 330–340.
Lawrie, SM, Whalley, HC, Abukmeil, SS, Kestelman, JN, Miller, P, Best, JJK, Owens, DGC, Johnstone, EC (2002). Temporal lobe volume changes in people at high risk of schizophrenia with psychotic symptoms. British Journal of Psychiatry 181, 138–143.
Lawrie, SM, Whalley, H, Kestelman, JN, Abukmeil, SS, Byrne, M, Hodges, A, Rimmington, JE, Best, JJK, Owens, DGC, Johnstone, EC (1999). Magnetic resonance imaging of brain in people at high risk of developing schizophrenia. Lancet 353, 30–33.
Lopez-Larson, MP, Bogorodzki, P, Rogowska, J, McGlade, E, King, JB, Terry, J, Yurgelun-Todd, D (2011). Altered prefrontal and insular cortical thickness in adolescent marijuana users. Behavioural Brain Research 220, 164–172.
Martín-Santos, R, Fagundo, AB, Crippa, JA, Atakan, Z, Bhattacharyya, S, Allen, P, Fusar-Poli, P, Borgwardt, S, Seal, M, Busatto, GF (2010). Neuroimaging in cannabis use: a systematic review of the literature. Psychological Medicine 40, 383–398.
McDonald, C, Bullmore, E, Sham, P, Chitnis, X, Suckling, J, MacCabe, J, Walshe, M, Murray, RM (2005). Regional volume deviations of brain structure in schizophrenia and psychotic bipolar disorder. Computational morphometry study. British Journal of Psychiatry 186, 369–377.
McIntosh, AM, Job, DE, Moorhead, WJ, Harrison, LK, Whalley, HC, Johnstone, EC, Lawrie, SM (2006). Genetic liability to schizophrenia or bipolar disorder and its relationship to brain structure. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 141B, 76–83.
McIntosh, AM, Owens, DC, Moorhead, WJ, Whalley, HC, Stanfield, AC, Hall, J, Johnstone, EC, Lawrie, SM (2011). Longitudinal volume reductions in people at high genetic risk of schizophrenia as they develop psychosis. Biological Psychiatry 69, 953–958.
Moorhead, TWJ, McKirdy, J, Sussmann, JED, Hall, J, Lawrie, SM, Johnstone, EC, McIntosh, AM (2007). Progressive gray matter loss in patients with bipolar disorder. Biological Psychiatry 62, 894–900.
Nelson, MD, Saykin, AJ, Flashman, LA, Riordan, HJ (1998). Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging: a meta-analytic study. Archives of General Psychiatry 55, 433–440.
Pantelis, C, Velakoulis, D, McGorry, PD, Wood, SJ, Suckling, J, Phillips, LJ, Yung, AR, Bullmore, ET, Brewer, W, Soulsby, B (2003). Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 361, 281–288.
Phillips, LJ, Curry, C, Yung, AR, Yuen, HP, Adlard, S, McGorry, PD (2002). Cannabis use is not associated with the development of psychosis in an ‘ultra’ high-risk group. Australian and New Zealand Journal of Psychiatry 36, 800–806.
Quickfall, J, Crockford, D (2006). Brain neuroimaging in cannabis use: a review. Journal of Neuropsychiatry and Clinical Neurosciences 18, 318–332.
Rais, M, Cahn, W, van Haren, N, Schnack, H, Caspers, E, Hulshoff Pol, H, Kahn, R (2008). Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. American Journal of Psychiatry 165, 490–496.
Semple, DM, McIntosh, AM, Lawrie, SM (2005). Cannabis as a risk factor for psychosis: systematic review. Journal of Psychopharmacology 19, 187–194.
Steen, RG, Mull, C, McClure, R, Hamer, RM, Lieberman, JA (2006). Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. British Journal of Psychiatry 188, 510–518.
Stone, JM, Bhattacharyya, S, Barker, GJ, McGuire, PK (2012). Substance use and regional gray matter volume in individuals at high risk of psychosis. European Neuropsychopharmacology 22, 114–122.
Sun, D, Phillips, L, Velakoulis, D, Yung, A, McGorry, PD, Wood, SJ, van Erp, TGM, Thompson, PM, Toga, AW, Cannon, TD (2009). Progressive brain structural changes mapped as psychosis develops in ‘at risk’ individuals. Schizophrenia Research 108, 85–92.
Talairach, J, Tournoux, P (1988). Co-planar Stereotaxic Atlas of the Human Brain: 3-Dimensional Proportional System: An Approach to Cerebral Imaging. Thieme: Stuttgart.
van Os, J, Kenis, G, Rutten, BPF (2010). The environment and schizophrenia. Nature 468, 203–212.
van Winkel, R, Kahn, RS, Linszen, DH, van Os, J, Wiersma, D, Bruggeman, R, Cahn, W, de Haan, L, Krabbendam, L, Myin-Germeys, I (2011). Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up. Archives of General Psychiatry 68, 148–157.
Vita, A, De Peri, L, Silenzi, C, Dieci, M (2006). Brain morphology in first-episode schizophrenia: a meta-analysis of quantitative magnetic resonance imaging studies. Schizophrenia Research 82, 75–88.
Welch, KA, McIntosh, AM, Job, DE, Whalley, HC, Moorhead, TW, Hall, J, Owens, DGC, Lawrie, SM, Johnstone, EC (2011 a). The impact of substance use on brain structure in people at high risk of developing schizophrenia. Schizophrenia Bulletin 37, 1066–1076.
Welch, KA, Stanfield, AC, McIntosh, AM, Whalley, HC, Job, DE, Moorhead, TW, Hall, J, Owens, DGC, Lawrie, SM, Johnstone, EC (2011 b). The impact of cannabis use on thalamic volume in people at familial high risk of schizophrenia. British Journal of Psychiatry 199, 386–390.
Whalley, HC, Kestelman, JN, Rimmington, JE, Kelso, A, Abukmeil, SS, Best, JJK, Johnstone, EC, Lawrie, SM (1999). Methodological issues in volumetric magnetic resonance imaging of the brain in the Edinburgh High Risk Project. Psychiatry Research 91, 31–44.
Whitford, TJ, Grieve, SM, Farrow, TFD, Gomes, L, Brennan, J, Harris, AWF, Gordon, E, Williams, LM (2006). Progressive grey matter atrophy over the first 2–3 years of illness in first-episode schizophrenia: a tensor-based morphometry study. NeuroImage 32, 511–519.
Wood, SJ, Kennedy, D, Phillips, LJ, Seal, ML, Yücel, M, Nelson, B, Yung, AR, Jackson, G, McGorry, PD, Velakoulis, D (2010). Hippocampal pathology in individuals at ultra-high risk for psychosis: a multi-modal magnetic resonance study. NeuroImage 52, 62–68.
Wood, SJ, Pantelis, C, Velakoulis, D, Yücel, M, Fornito, A, McGorry, PD (2008). Progressive changes in the development toward schizophrenia: studies in subjects at increased symptomatic risk. Schizophrenia Bulletin 34, 322–329.
Wright, IC, Rabe-Hesketh, S, Woodruff, PWR, David, AS, Murray, RM, Bullmore, ET (2000). Meta-analysis of regional brain volumes in schizophrenia. American Journal of Psychiatry 157, 16–25.
Yücel, M, Solowij, N, Respondek, C, Whittle, S, Fornito, A, Pantelis, C, Lubman, DI (2008). Regional brain abnormalities associated with long-term heavy cannabis use. Archives of General Psychiatry 65, 694–701.
Zammit, S, Moore, THM, Lingford-Hughes, A, Barnes, TRE, Jones, PB, Burke, M, Lewis, G (2008). Effects of cannabis use on outcomes of psychotic disorders: systematic review. British Journal of Psychiatry 193, 357–363.